A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study

BACKGROUND: Adalimumab is an effective and safe biological drug for the treatment of inflammatory bowel disease (IBD). Nowadays, several biosimilar agents are available, but data regarding their efficacy and safety in patients with IBD are still lacking. We aimed to compare the effectiveness and tol...

Descripción completa

Detalles Bibliográficos
Autores principales: Barberio, Brigida, Cingolani, Linda, Canova, Cristina, Barbieri, Giulia, Sablich, Renato, Urbano, Maria Teresa, Bertani, Lorenzo, Costa, Francesco, Bodini, Giorgia, Demarzo, Maria Giulia, Ferronato, Antonio, Buda, Andrea, Melatti, Piera, Massimi, Davide, Savarino, Edoardo Vincenzo, Zingone, Fabiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295962/
https://www.ncbi.nlm.nih.gov/pubmed/34349836
http://dx.doi.org/10.1177/17562848211031420

Ejemplares similares

Ejemplares similares